Laurus Labs

Update in progress

LAURUSLABS.NS (NSE)

Company RatingNeutral
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic

Laurus Labs Limited and its subsidiaries manufacture and sell medicines and active pharmaceutical ingredients (APIs) in India and abroad. It offers generics APIs and oral solid formulations across ARV, antidiabetic, cardiovascular, anti-asthma, ophthalmology, oncology, gastroenterology and hepatitis C. The company provides biotech services for nutraceuticals, dietary supplements and cosmeceuticals, plus enzymatic solutions for industrial biotech and animal-origin-free recombinant proteins for biopharma, with pharma business support services. Incorporated in 2005, based in Hyderabad, India.

Company score

Sentiment: 0.39; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.00; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: 0.32; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: 0.08; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: 0.11; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: 0.25; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive